This paper examines biosafety management in high-biosafety-risk workshops for vaccine production in China, focusing on the context of SARS-CoV-2 inactivated vaccine production. It addresses various aspects, including biosafety management, personnel, virus seed, facilities, and equipment, and compliance with relevant biosafety laws and regulations. The aim is to promote the use of high-level biosafety facilities when dealing with emerging infectious diseases.
Full Text Finder